HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease.
HeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe and Japan. For more information, visit www.heartflow.com.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 13, 2019 | Series Unknown | $64.99M | — | — | — | Detail |
Nov 29, 2017 | Series E | $240M | 4 | — | — | Detail |
May 20, 2016 | Series D | $99.93M | 1 | Panorama Point Partners | — | Detail |
Feb 12, 2015 | Series Unknown | $35.88M | — | — | — | Detail |
Feb 26, 2014 | Series C | $104.69M | 2 | Capricorn Investment Group | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Panorama Point Partners | Yes | Series D |
Capricorn Investment Group | Yes | Series C |
Baillie Gifford | — | Series E |
Martis Capital | — | Series E |
Rancilio Cube | — | Series E |
Wellington Management | — | Series E |
Lifeforce Capital | — | Series C |
Emergent Medical Partners | — | Seed |
HealthCor Partners | — | Seed |
U.S. Venture Partners | — | Seed |